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Background: Primary infection with or reactivation of varicella zoster virus (VZV) can cause neurologic
complications, which typically result in an intrathecal production of VZV-specific antibodies. Intrathecal antibodies to
VZV are detectable by an elevated antibody index (AI). However, elevated VZV AIs are also found in more than half
of patients with multiple sclerosis (MS), where they are thought to be part of a polyspecific intrathecal immune
response. Determination of the fraction of intrathecally-produced virus-specific antibodies among all intrathecally
produced antibodies may discriminate between virus-specific and polyspecific intrathecal immune responses, but
the fraction of intrathecally-produced VZV-specific immunoglobulin (Ig)G of the total intrathecally produced IgG
(FS anti-VZV) in patients with MS and VZV reactivation has hitherto not been compared.
Findings: FS anti-VZV was calculated in patients with a clinically isolated syndrome suggestive of multiple sclerosis
(MS) or MS (n = 20) and in patients with VZV reactivation (7 samples from 5 patients), which all had elevated VZV
AIs. The median FS anti-VZV was 35-fold higher in patients with VZV reactivation (45.1%, range 13.5-73%) than in
patients with CIS/MS (1.3%, range 0.3-5.3%; p = 0.0001). While there was thus no overlap of FS anti-VZV values
between groups, VZV AIs completely overlapped in patients with CIS/MS (1.6-14.8) and VZV reactivation (2.1-8.1).
Conclusions: The fraction of intrathecally-produced VZV-specific IgG of the total intrathecally produced IgG
discriminates between patients with VZV reactivation and MS. Our results provide further evidence that
intrathecally-produced VZV antibodies are part of the polyspecific immune response in patients with MS.
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Both primary infection and reactivation of varicella zoster
virus (VZV) can cause various neurologic complications,
including meningitis, meningoencephalitis, cerebellitis,
myelitis, and cerebral vasculitis [1,2]. These conditions
typically lead to an intrathecal production of VZV-specific* Correspondence: klemens.ruprecht@charite.de
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unless otherwise stated.antibodies [3,4]. Intrathecally-produced VZV antibodies
can be detected by an elevated antibody index (AI), which
is the ratio between the CSF/serum quotient of virus-
specific antibodies (Qspec) and the CSF/serum quotient for
total IgG (QIgG) [4]. However, elevated VZV AIs are also
present in more than half of patients with multiple scler-
osis (MS), a chronic inflammatory demyelinating central
nervous system (CNS) disease, where they are thought to
be part of a polyspecific intrathecal immune response [5].
To characterize intrathecal antiviral immune responses in
detail, but also for clinical differential diagnostic purposes,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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AIs reflect virus-driven or polyspecific intrathecal immune
responses. Others and we have previously shown that this
can be achieved by calculating the fraction (FS) of the
intrathecally-synthesized virus-specific immunoglobulin
(Ig)G of the total intrathecally-synthesized IgG [5-7].
Nevertheless, the fraction of intrathecally-produced VZV-
specific IgG of the total intrathecally-produced IgG (FS
anti-VZV) in patients with VZV reactivation and MS has
hitherto not been compared. We herein show that calcula-
tion of FS anti-VZV allows discrimination between pa-
tients with VZV reactivation and MS.
Patients and methods
Patients
The study was approved by the institutional review board
Charité – Universitätsmedizin Berlin (EA1/068/12). All
lumbar punctures were performed for diagnostic purposes
only, with the patients’ written informed consent. Twenty
patients (14 female, 6 male; median [range] age 33 [21-60]
years) with an elevated VZV AI (defined as VZV AI ≥ 1.5)
and either a clinically isolated syndrome (CIS, n = 11) sug-
gestive of MS, relapsing-remitting MS (n = 8), or primary
progressive MS (n = 1) according to the McDonald 2005
criteria [8] were included in the study. All CIS/MS pa-
tients had an intrathecal IgG synthesis, demonstrated by
the presence of CSF-specific oligoclonal bands. We de-
fined CSF/serum samples obtained up to 4 weeks after the
onset of a clinical relapse as samples taken during a re-
lapse (n = 14) and CSF/serum samples obtained more than
4 weeks after a clinical relapse as samples taken during re-
mission (n = 6).
We identified 13 patients with CNS complications of
VZV reactivation, confirmed by PCR detection of VZV
DNA in CSF. Seven CSF/serum samples from five of
these patients (2 female, 3 male) met the requirements
for determination of FS, i.e. an intrathecal IgG synthesis
as proven by QIgG > Qmean and an intrathecal VZV-
specific antibody synthesis (VZV AI ≥ 1.5). The median
(range) age of these five patients was 68 (45-74) years
and their CSF/serum samples were drawn 19 (median,
range; 2-89) days after clinical onset of symptoms; clin-
ical diagnoses were VZV meningitis, VZV meningitis/
Ramsay Hunt syndrome, VZV meningitis/retinitis, VZV
encephalitis/vitritis, and VZV-associated cerebral vascu-
lopathy. We additionally analysed two patients (1 female,
1 male; 67 and 54 years) with herpes simplex virus
(HSV) encephalitis, proven by PCR detection of HSV
DNA in CSF, who had a QIgG > Qmean, and an intrathecal
VZV-specific antibody synthesis (VZV AIs 2 and 10.1).
Serum and cerebrospinal fluid (CSF) samples collected
between April 2004 and July 2012 and stored at -20°C,
were available from all patients. To exclude a confound-
ing influence of artificial blood contamination onantibody measurements, only CSF samples with an
erythrocyte count of < 400/μl were included [9].
Measurement and calculation of virus-specific antibody
indices
Total albumin and IgG concentrations in serum and CSF
were measured nephelometrically (BN ProSpec, Siemens
Healthcare Diagnostics, Eschborn, Germany). AIs for anti-
bodies against VZV were determined exactly as previously
described by enzyme-linked immunosorbent assays
(Enzygnost, Siemens Healthcare Diagnostics) [7]. A stand-
ard curve consisting of serial dilutions of standard human
plasma (SHP, Siemens Healthcare Diagnostics) was in-
cluded on each ELISA plate. The same batch of SHP was
used for all experiments. AI values were calculated either
by the formula: AI = (IgGspec CSF/IgGspec serum)/(IgGtotal
CSF/IgGtotal serum) = (quotient CSF/serum specific IgG)/
(quotient CSF/serum total IgG) =Qspec/QIgG if QIgG <
QLim, or AI =Qspec/QLim if QIgG >QLim [4]. QLim was cal-
culated as described [3].
Calculation of the intrathecal fraction of VZV-specific
antibodies
The fraction (in %) of the intrathecally-synthesized VZV-
specific IgG concentration of the total intrathecally-
synthesized IgG concentration (FS anti-VZV) was cal-
culated as described [6,7]. Calculation of FS anti-VZV
requires determination of the absolute concentration (in
μg/ml) of VZV-specific IgG antibodies in serum and CSF.
Therefore, samples must be tested in parallel with a
standard curve, for which we used SHP, with a known
concentration of VZV-specific IgG. Applying a previ-
ously-described method [7], we determined the absolute
concentration of anti-VZV antibodies in the SHP used in
this study to be 24 μg/ml.
FS values were determined as ratio of the intrathecally-
produced concentration of virus-specific antibodies
(ABLoc) and the concentration of intrathecally-
synthesized total IgG (IgGLoc). As previously described
[6], for comparison of means in different groups FS re-
fers to Qmean instead of QLim. Therefore, FS was calcu-
lated by the formula: FS = ABLoc (mean)/IgGLoc (mean) ×
100 [%], with IgGLoc (mean) = (QIgG – Qmean) × IgG
(serum) [mg/l], ABLoc (mean) = (Qspec - Qmean) × AB
(serum) [mg/l], and Qmean (IgG) = (0.65 (QAlb
2 + 8)0.5 –
1.4) × 10-3 [6]. Of note, FS can only be calculated for
QIgG > Qmean and in cases of a proven intrathecal virus-
specific antibody synthesis, as defined by an AI ≥ 1.5 [4].
Statistics
Statistical significance of different FS values in patients
with CIS/MS and VZV reactivation and in CIS/MS pa-
tients in relapse and remission was assessed by Mann–
Whitney U test using GraphPad Prism 5.04 software.
Figure 1 Percentage of VZV-specific intrathecally-produced IgG
of the total intrathecally-produced IgG (FS anti-VZV) in patients
with a clinically isolated syndrome or multiple sclerosis
(CIS/MS) and VZV reactivation with central nervous system
complications (VZV). An FS anti-VZV of 5% is indicated by the
dashed line. Statistical significance of the difference between groups
was assessed by Mann–Whitney U test.
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The median FS anti-VZV in the 20 patients with CIS/MS
was 1.3%, indicating that in these patients 1.3% (median) of
all intrathecally produced antibodies were directed against
VZV (Table 1, Figure 1). In contrast, median FS anti-VZV
in the 7 CSF/serum pairs from 5 patients with VZV reacti-
vation was 45.1% (VZV meningitis, 13.5%; VZV meningi-
tis/Ramsay Hunt syndrome, 30.2% and 39.8%; VZV
meningitis/retinitis, 45.1%; VZV encephalitis/vitritis, 73%
and 45.8%; VZV-associated cerebral vasculopathy, 64.6%).
Thus, the median amount of intrathecally-synthesized
anti-VZV antibodies was 35-fold higher in patients with
VZV reactivation compared to patients with CIS/MS (p =
0.0001). There was no overlap of FS anti-VZV values be-
tween patients with CIS/MS and VZV reactivation. Con-
versely, VZV AI values overlapped between both groups,
re-confirming that AIs do not discriminate between a
virus-driven and a polyspecific intrathecal immune re-
sponse. A comparison of FS anti-VZV between CIS/MS pa-
tients in relapse and remission revealed no significant
difference (p = 0.34). To confirm the specificity of elevated
FS anti-VZV values for VZV reactivation we additionally
determined FS anti-VZV in 2 patients with HSV encephal-
itis with a concomitant intrathecal VZV antibody synthesis.
FS anti-VZV values of these 2 patients (0.3% and 4.96%)
were in the same range as those of patients with CIS/MS.
Discussion
This study shows that FS anti-VZV is about 35-fold higher
in patients with VZV reactivation than in patients with
CIS/MS. FS anti-VZV values did not overlap between both
groups, suggesting that determination of FS anti-VZV can
accurately discriminate between a polyspecific immune re-
sponse in CIS/MS and a virus-specific immune response in
VZV reactivation. This is in accordance with previous re-
ports demonstrating that patients with HSV encephalitis,
subacute sclerosing panencephalitis (SSPE), or Epstein-Barr
virus (EBV) replication in the CNS have a fraction of the
intrathecally-produced virus-specific IgG that is 20- to 60-
fold higher than in patients with MS [6,7]. In HSV enceph-
alitis, SSPE, or EBV replication in the CNS a median of 9%,
19%, and 28% of the total intrathecally synthesized IgG was
found to be directed against HSV, measles virus, or EBV,
respectively [6,7]. The median FS anti-VZV observed in this
work was even higher (45.1%), indicating that VZVTable 1 Intrathecal VZV-specific immune responses in patient
IgGLoc (mean) (mg/l) ABLoc (mean) (mg/l)
CIS/MS (n = 20) 44.2 (5.6-103.1) 0.5 (0.1-4.5)
VZV (n = 7)* 20.7 (5.2-89.2) 8 (0.7-40.2)
Median (range) of intrathecally-synthesized total IgG (IgGLoc (mean)), intrathecally-s
serum (AB (serum)), antibody index (AI), and intrathecally-produced fraction of VZV
multiple sclerosis (CIS/MS) and VZV reactivation with central nervous system compl
*7 CSF/serum samples from 5 patients.
**p = 0.0001 (CIS/MS vs. VZV).reactivation with CNS complications results in a highly-
focussed VZV-specific intrathecal antibody response. Con-
sistent with previous observations in 4 patients with HSV
encephalitis [6], the FS anti-VZV values determined in 2 pa-
tients with HSV encephalitis in this work were in the same
range as those of CIS/MS patients, suggesting that intra-
thecal production of VZV antibodies represents a formerly-
recognized non-specific anti-VZV antibody synthesis in pa-
tients with HSV encephalitis [3] and that the levels of FS
anti-VZV elevation in patients with VZV reactivation ob-
served in the present study might be specific for this condi-
tion. Nevertheless, further studies involving larger patient
numbers will be required to establish more definitively the
specificity of elevated FS anti-VZV values for VZV reactiva-
tion and to determine a cut-off above which elevated
FS anti-VZV values can be considered specific for VZV
reactivation.s with CIS/MS and VZV reactivation
AB (serum) (mg/l) AI FS anti-VZV (%)**
51 (7.6-353) 3.9 (1.6-14.8) 1.3 (0.3-5.3)
244 (42.4-962) 6.9 (2.1-8.1) 45.1 (13.5-73)
ynthesized VZV-specific IgG (ABLoc (mean)), anti-VZV antibody concentration in
-specific antibodies (FS) in patients with a clinically isolated syndrome or
ications (VZV).
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the same range as previously reported FS values for VZV,
HSV, measles virus, rubella virus, and EBV in patients with
CIS/MS [6,7]. The similar FS values for VZV, HSV, measles
virus, rubella virus, and EBV in patients with CIS/MS as
well as the marked difference in FS anti-VZV between pa-
tients with CIS/MS and VZV reactivation, strongly suggest
that the intrathecal production of VZV antibodies is part
of the polyspecific intrathecal humoral immune response
in MS. Our finding that FS anti-VZV values did not differ
between CIS/MS patients in relapse and remission does
not support the idea that FS anti-VZV could be influenced
by clinical disease activity.
A previous study reported the presence of VZV DNA in
CSF of patients with MS during relapses, leading to the
proposal of a participation of VZV in the pathogenesis of
MS [10,11]. However, those findings could not be repro-
duced [12]. Likewise, our results indicating that VZV anti-
bodies are part of the polyspecific intrathecal immune
response in MS argue against the presence of VZV in the
CSF of the CIS/MS patients investigated in this study.
An intrathecal IgG synthesis is found in ~95% of pa-
tients with MS [5]. Together with previous work [6,7], our
results underscore that this intrathecally produced IgG is
indeed polyspecific with only a small proportion of the
intrathecally produced IgG being directed against each
particular antigen target. The fact that this is already evi-
dent in patients with a CIS is compatible with the concept
that a variety of different plasma cell clones populate the
CNS early during the development of MS.
One limitation of this study is its relatively small patient
numbers. Especially, the number of patients with VZV re-
activation was limited as less than half of these patients
met the requirements for determination of FS anti-VZV
(QIgG > Qmean and VZV AI ≥1.5). Nevertheless, the differ-
ence between both groups was clear-cut, highly significant,
and corresponded well to previous findings on the intra-
thecal production of antiviral antibodies in MS.
Conclusions
Altogether, our study demonstrates that determination of
FS anti-VZV allows discrimination between patients with
VZV reactivation and CIS/MS. It also provides further evi-
dence that intrathecally produced VZV antibodies are part
of the polyspecific immune response in MS. Determin-
ation of FS can be applied to any intrathecally produced
microorganism- or antigen-specific antibody and may
therefore prove a useful tool to differentiate between
microorganism/antigen-triggered and polyspecific intra-
thecal humoral immune responses in different contexts
and diseases.
Competing interests
CO, JH, CF, and MZ report no disclosures. KR has received speaker’s honoraria
and travel grants from Merck Serono, Teva, Biogen Idec, Novartis PharmaGmbH, and Bayer Schering as well as scientific grant support from Novartis
Pharma GmbH. KR is supported by the German ministry of education and
research (BMBF/KKNMS, Competence Network Multiple Sclerosis).
Authors’ contributions
CO participated in the design of the study, carried out the experiments, and
collected and analyzed data, JH participated in the design of the study and
analyzed data, CF and MZ collected and analyzed data, KR conceived of the
study, participated in the design of the study, analyzed data, and wrote the
manuscript. All authors read and approved the manuscript.
Acknowledgements
The authors like to thank Sigrid Kersten, Gabriele Kerger, Severine Lepek, and
Simone Wolf for excellent technical assistance. This work was supported by
the Charité Research Fund.
Author details
1Department of Neurology, Charité – Universitätsmedizin Berlin,
Charitéplatz 1, 10117 Berlin, Germany. 2Labor Berlin, Charité-Vivantes GmbH
and Institute for Virology, Charité – Universitätsmedizin Berlin, Charitéplatz 1,
10117, Berlin, Germany. 3Labor Berlin, Charité-Vivantes GmbH and Institute of
Laboratory Medicine, Clinical Chemistry, and Pathobiochemistry, Charité -
Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
4Clinical and Experimental Multiple Sclerosis Research Center,
Charité – Universitätsmedizin Berlin, Berlin, Germany.
Received: 16 October 2013 Accepted: 8 February 2014
Published: 12 February 2014
References
1. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs
RJ: Neurologic complications of the reactivation of varicella-zoster virus.
N Engl J Med 2000, 342:635–645.
2. Gilden D, Mahalingam R, Nagel MA, Pugazhenthi S, Cohrs RJ: Review: The
neurobiology of varicella zoster virus infection. Neuropathol Appl Neurobiol
2011, 37:441–463.
3. Reiber H, Peter JB: Cerebrospinal fluid analysis: disease-related data
patterns and evaluation programs. J Neurol Sci 2001, 184:101–122.
4. Reiber H, Lange P: Quantification of virus-specific antibodies in
cerebrospinal fluid and serum: sensitive and specific detection of
antibody synthesis in brain. Clin Chem 1991, 37:1153–1160.
5. Reiber H, Ungefehr S, Jacobi C: The intrathecal, polyspecific and oligoclonal
immune response in multiple sclerosis. Mult Scler 1998, 4:111–117.
6. Jacobi C, Lange P, Reiber H: Quantitation of intrathecal antibodies in
cerebrospinal fluid of subacute sclerosing panencephalitis, herpes simplex
encephalitis and multiple sclerosis: discrimination between microorganism-
driven and polyspecific immune response. J Neuroimmunol 2007, 187:139–146.
7. Otto C, Oltmann A, Stein A, Frenzel K, Schroeter J, Habbel P, Gartner B, Hofmann
J, Ruprecht K: Intrathecal EBV antibodies are part of the polyspecific immune
response in multiple sclerosis. Neurology 2011, 76:1316–1321.
8. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin
FD, Metz LM, McFarland HF, O’Connor PW, et al: Diagnostic criteria for
multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol
2005, 58:840–846.
9. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M,
Franciotta D, Frederiksen JL, Fleming JO, Furlan R, et al: A consensus
protocol for the standardization of cerebrospinal fluid collection and
biobanking. Neurology 2009, 73:1914–1922.
10. Sotelo J, Martinez-Palomo A, Ordonez G, Pineda B: Varicella-zoster virus in cere-
brospinal fluid at relapses of multiple sclerosis. Ann Neurol 2008, 63:303–311.
11. Sotelo J, Corona T: Varicella zoster virus and relapsing remitting multiple
sclerosis. Mult Scler Int 2011, 2011:214763.
12. Burgoon MP, Cohrs RJ, Bennett JL, Anderson SW, Ritchie AM, Cepok S,
Hemmer B, Gilden D, Owens GP: Varicella zoster virus is not a disease-
relevant antigen in multiple sclerosis. Ann Neurol 2009, 65:474–479.
doi:10.1186/2045-8118-11-3
Cite this article as: Otto et al.: The fraction of varicella zoster virus-
specific antibodies among all intrathecally-produced antibodies
discriminates between patients with varicella zoster virus reactivation
and multiple sclerosis. Fluids and Barriers of the CNS 2014 11:3.
